CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-27 | BATE KENNETH Director | Sale | −238 | $353.83 | $84K | 21,074 |
| 2025-02-27 | BATE KENNETH Director | Sale | −8,545 | $355.08 | $3.0M | 12,529 |
| 2025-02-27 | BATE KENNETH Director | Sale | −2,791 | $356.51 | $995K | 9,738 |
| 2025-02-27 | BATE KENNETH Director | Sale | −2,038 | $357.27 | $728K | 7,700 |
| 2025-02-27 | BATE KENNETH Director | Sale | −3,548 | $358.33 | $1.3M | 4,152 |
| 2025-02-27 | BATE KENNETH Director | Sale | −2,024 | $359.21 | $727K | 2,128 |
| 2025-02-27 | BATE KENNETH Director | Sale | −216 | $360.07 | $78K | 1,912 |
| 2025-02-27 | BATE KENNETH Director | Option exercise · Stock Option (Right to Buy) | −6,000 | 0 | ||
| 2025-02-27 | BATE KENNETH Director | Option exercise · Stock Option (Right to Buy) | −9,470 | 0 | ||
| 2025-02-27 | BATE KENNETH Director | Option exercise · Stock Option (Right to Buy) | −4,530 | 5,470 | ||
| 2025-01-24 | Huntsman Carole Chief Commercial Officer | Sale | −347 | $335.24 | $116K | 10,438 |
| 2025-01-24 | Sibold William John President and CEO | Sale | −1,584 | $335.24 | $531K | 54,303 |
| 2025-01-24 | Taub Rebecca Pres., R&D, and CMO | Sale | −648 | $335.24 | $217K | 456,662 |
| 2025-01-24 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −103 | $335.24 | $35K | 4,955 |
| 2025-01-17 | Kelley Shannon T General Counsel | Sale | −277 | $273.41 | $76K | 7,705 |
| 2025-01-17 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −442 | $273.41 | $121K | 5,058 |
| 2025-01-17 | Taub Rebecca Pres., R&D, and CMO | Sale | −1,689 | $273.41 | $462K | 457,310 |
| 2024-12-03 | CRAVES FRED B Director | Sale | −3,080 | $315.21 | $971K | 11,520 |
| 2024-12-03 | CRAVES FRED B Director | Sale | −520 | $315.90 | $164K | 11,000 |
| 2024-11-25 | CRAVES FRED B Director | Sale | −2,200 | $350.08 | $770K | 15,800 |
Page 27 of 82 · 1,629 trades